The role of cortical disinhibition in a progressive mouse model of parkinson’s disease Public Deposited
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by declining motor function. While the etiology is not understood, a hallmark of PD is a loss of dopaminergic cells in the substantia nigra pars compacta (SNpc), which provide the dopamine tone for the basal ganglia. The decline in dopamine levels in the striatum, the projection target of the SNpc, leads to a dysregulation of signaling between the nuclei of the basal ganglia, leading to decreased output from the motor thalamus and consequent motor dysfunction. Current therapies provide symptomatic relief, but to date, no treatment has been proven capable of altering PD progression, necessitating the need for a different treatment strategy.